# Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)

> **NCT07033689** · EARLY_PHASE1 · RECRUITING · sponsor: **SONIRE Therapeutics Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DEVICE:** Suizenji (an ultrasound-guided HIFU therapy system)
- **DRUG:** Nal-IRI/FL
- **DRUG:** mFOLFIRINOX adjuvant chemotherapy
- **DRUG:** Gem/nab-PTX

## Key facts

- **NCT ID:** NCT07033689
- **Lead sponsor:** SONIRE Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07033689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07033689, "Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07033689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*